INDIANAPOLIS — The diabetes treatment 'Trulicity' helped push Eli Lilly to a better-than-expected second quarter. It led the company to raise its 2019 forecast.
The Indianapolis-based pharmaceutical company said revenue from Trulicity — a once-weekly diabetes treatment — climbed 32 percent to $1 billion.
Overall, Lilly earned $1.33 billion in a three-month period that ended June 30. That compares to a loss of about $260 million in last year's quarter.
